ITCI: קפיטליזציית שוק intracellulartherapies.com
The historical price chart for Intra-Cellular Therapies (ITCI) reflects the dynamics of an asset whose R&D potential is currently peaking as it prepares to expand the application of Caplyta for depression. Market capitalization stands at 13.99, while the business relies on stable, non-cyclical demand within the psychiatry sector. Strong positioning is secured by rigorous patent protection and physician trust, which effectively curbs the expansion of new market entrants.
ITCI (intracellulartherapies.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The market capitalization of Intra-Cellular Therapies (ITCI) reflects the aggregate value of all shares, assessing the potential of its molecular platform in psychiatry. This metric is calculated as the product of the current share price and the total number of outstanding securities. By analyzing the company's market capitalization, an investor can discern the market consensus regarding the commercial success of Caplyta. This chart's price action smooths out short-term speculation, revealing a sustainable valuation trend. Avoid buying at local peaks to prevent capital from being locked up.